| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Compound 6q targets the NF-κB signaling pathway. It acts as an anti-inflammatory agent by downregulating NF-κB signaling through suppression of the Akt/PI3K pathway. By inhibiting NF-κB activation, Compound 6q reduces the production of pro-inflammatory mediators such as nitric oxide (NO).
|
|---|---|
| ln Vitro |
In vitro, Compound 6q effectively inhibits LPS-stimulated nitric oxide (NO) production in RAW 264.7 macrophages. It potently downregulates NF-κB signaling via suppression of the Akt/PI3K pathway. The compound shows high anti-inflammatory activity in cell-based assays.
|
| ln Vivo |
In vivo, Compound 6q demonstrates high anti-inflammatory activities in a mouse colitis model induced by dextran sulfate sodium (DSS). This suggests potential for the treatment of inflammatory bowel diseases (IBD). Specific dosing regimens and efficacy data have not been detailed in the available sources.
|
| Enzyme Assay |
The in vitro assay for Compound 6q involves measuring its inhibition of nitric oxide (NO) production. RAW 264.7 macrophages are stimulated with LPS in the presence of varying compound concentrations. Nitrite levels in the culture medium are measured using the Griess assay. The compound's anti-inflammatory activity is determined from dose-response curves.
|
| Cell Assay |
Cellular assays for Compound 6q are performed using RAW 264.7 macrophages. Cells are treated with Compound 6q and stimulated with LPS. NF-κB activation is assessed by measuring the phosphorylation of IκB or by EMSA. Akt/PI3K pathway activity is assessed by Western blotting.
|
| Animal Protocol |
In vivo animal studies for Compound 6q are conducted in a mouse colitis model induced by dextran sulfate sodium (DSS). The compound is administered orally or by injection. Anti-inflammatory activity is assessed by measuring disease activity index, colon length, and histological scoring.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Compound 6q are not available in the provided sources. The compound is a steroidal anti-inflammatory agent. Specific PK parameters such as half-life, bioavailability, and clearance have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicity data for Compound 6q are not reported in the available sources. As a research compound, it is not intended for therapeutic use. The compound has been evaluated in animal models of colitis. Specific toxicological profiles have not been characterized.
|
| References | |
| Additional Infomation |
Compound 6q is a research compound being investigated for the treatment of inflammatory bowel diseases (IBD). It is a novel steroidal anti-inflammatory agent that downregulates NF-κB signaling via the Akt/PI3K pathway. The compound has demonstrated high in vivo anti-inflammatory activities in a mouse colitis model. It is available from commercial suppliers for research purposes.
|
| Exact Mass |
366.23
|
|---|---|
| Elemental Analysis |
C, 75.37 H, 8.25 N, 7.64 O, 8.73
|
| Appearance |
Typically exists as solid at room temperature
|
| Chemical Name |
C23H30N2O2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
